Skip to content Skip to footer
Subscribe Now
PharmaShots' Key Highlights of Second Quarter 2022
INSIGHTS+
PharmaShots’ Key Highlights of Second Quarter 2022
The second quarter of 2022 highlights major acquisitions in the pharma and biotech industry along with multiple approvals. Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) meet its primary endpoints for heart failure with a preserved ejection fractionStarting with the latest acquisitions, Pfizer acquire Biohaven for ~$11.6B, GSK acquire Affinivax for ~$3.3B. The second quarter of the year…
June 30, 20220Comments
PharmaShots Interview In Conversation with ViiV Healthcare's Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV
VIEWPOINTS
PharmaShots Interview: In Conversation with ViiV Healthcare’s Sr. VP, Kimberly Smith, Where she Shares Insights on the US FDA Approval for Label Update of its Lead Candidate in HIV
Shots:Kimberly talked about the approval for label update of ViiV’s lead candidate in HIV, and how an optional oral lead-in will be efficient for people receiving itKimberly also spoke about ViiV’s collaboration with Janssen for the commercialization of the product The interview gives an understanding of the different treatment options for HIV and…
June 29, 20220Comments
PharmaShots Interview In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022
VIEWPOINTS
PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022
ShotsMai-Britt talked about the P-I/II clinical trial data and study design of its lead candidate in metastatic melanoma in an e-poster presentation at AACR 2022She also spoke about IO Biotech’s unique platform with tumor defense mechanisms to kill cancer cellsThe interview gives a profound understanding of how IO Biotech is advancing to…
June 28, 20220Comments
PharmaShots Interview In Conversation with Four Prominent Leaders from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
VIEWPOINTS
PharmaShots Interview: In Conversation with Four Prominent Leaders* from Eisai Where they Share Insights on New Alzheimer’s Data Presented at the Alzheimer’s & Parkinson’s Disease Conference
Shots:The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD ConferenceThe spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
June 27, 20220Comments
PharmaShots Interview In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
VIEWPOINTS
PharmaShots Interview: In Conversation with SOTIO’s CMO, Richard Sachse, Where he Shares Insights on New Interim Data presented in an Oral Presentation at AACR 2022 Annual Meeting
Shots:Richard spoke about the results from the Phase 1 AURELIO-03 study of IL-15 superagonistRichard also emphasized the clinical benefits of the IL-15 superagonist when combined with pembrolizumabThe interview gives a profound understanding of the existing & developing cancer therapies as treatment options for solid tumorsSmriti: Explain the details (MOA, ROA, formulations, etc.)…
June 22, 20220Comments
PharmaShots Interview In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)
VIEWPOINTS
PharmaShots Interview: In Conversation with Cecelia’s CMO, Arnold Saperstein, Where he Shares Insights on Improving Outcomes for Children and Adolescents Living With Type 1 Diabetes (T1D)
Shots:Arnold spoke about Cecelia Health’s collaboration with the UBMD Paediatrics for a clinical study to improve health outcomes for children and adolescents living with T1DArnold also gave his views on how telehealth options can support the unmet needs of patients with T1DThe interview provides a gist of the challenges of living with…
June 20, 20220Comments